This comprehensive meta-analysis demonstrated that licensed asthma biologics reduce exacerbations and hospitalisations, improve lung function, asthma control and quality of life, and limit the use of systemic corticosteroids, with a favourable safety profile. These effects are more prominent in patients with evidence of type 2 inflammation.
Read the pick of the week | Submit your manuscript to the European Respiratory Review
No comments:
Post a Comment